Macular Pigment and Visual Performance in Glaucoma Patients

• Status: Recruiting
• Trial end date: 2021-12-31
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine cross-sectional relationships between macular pigment optical density (MPOD) and visual performance in glaucoma. Additionally, the investigators wish to determine the effect of lutein, zeaxanthin, and mesozeaxanthin supplementation on MPOD and visual performance in glaucoma patients.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Duke University; Felipe Medeiros, MD
• Collaborators: Heidelberg Engineering GmbH; Industrial Orgánica S.A. de C.V.; MacuHealth LP
• Treatments: Carotenoids

Criteria

Inclusion Criteria:

• glaucoma diagnosis: To be considered glaucomatous, patients will be required to have:

(1) history of elevated intraocular pressure (IOP; over 21 mmHg); (2) at least two consecutive and reliable standard automated perimetry (SAP) examinations with either a pattern standard deviation (PSD) outside the 95% normal limits or a glaucoma hemifield test (GHT) result outside the 99% normal limits; and/or glaucomatous optic neuropathy.

• between the ages of 18 and 75 years,

• must be able and willing to provide signed informed consent and follow study instructions.

Exclusion Criteria:

• no systemic disease, no other ocular disease